Nicholas Flytzanis, Ph.D.

Founder, Chief Scientific Officer


Nicholas Flytzanis co-founded Capsida Biotherapeutics and serves as Chief Scientific Officer. Prior to co-founding Capsida, Dr. Flytzanis served as scientific director of the CLOVER research center at the California Institute of Technology (Caltech), leading an interdisciplinary team to develop and disseminate emerging technologies focused on the cross-section of neurological research and gene therapy. His research spans the fields of tissue clearing and imaging, optogenetics and rodent behavior, and adeno-associated virus (AAV) engineering and gene therapy, with collaborations across multiple institutions. During his Ph.D., Dr. Flytzanis applied protein engineering and directed evolution across biological modalities, with a focus on developing AAVs as therapeutic tools for neurological disease.

Dr. Flytzanis holds a B.S. in biology from the Massachusetts Institute of Technology and a Ph.D. in biology from Caltech.


BACK TO TEAM